Approval · Notice of Compliance 21466 · 2018
ATACAND PLUS: Notice of Compliance 21466
Issued October 26, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21466
- Date
- October 26, 2018
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to outer carton labels to comply witih pll and add a statement to minimize risk in pregnancy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ATACAND PLUS | Not yet assigned | — |
Medicinal ingredients
- HYDROCHLOROTHIAZIDE 12.5 MG per TAB
- CANDESARTAN CILEXETIL 16 MG per TAB
- CANDESARTAN CILEXETIL 32 MG per TAB
- HYDROCHLOROTHIAZIDE 25 MG per TAB